SEC INSIDER TRANSACTIONS

METLIFE INC (MET-PF) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

MET-PF · METLIFE INC

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 44 filings · fetched 2026-11-13T18:57:13Z

Recent reported activity

0purchase rows on this page

1sale rows on this page

56matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F7	M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	94,578D	0	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F6	M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	90,726D	0	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F5	M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	34,608D	0	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F3, F4	M Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	28,817D	0	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	187,425D	102.9676	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References:	M Exercise / conversionCommon Stock · Non-derivative	94,578A	47.58	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References:	M Exercise / conversionCommon Stock · Non-derivative	90,726A	44.65	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References:	M Exercise / conversionCommon Stock · Non-derivative	34,608A	45.5	Direct	Form 4 ↗0001535491-26-000007
2026-11-10Filed 2026-11-12	Khalaf MichelDirector · Officer · President & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The reporting person sold only the number of shares of MetLife, Inc.'s common stock necessary to pay the exercise price of the options exercised on November 10, 2026, and related tax obligations and fees. F2 The price reported is the weighted average price of the aggregate number of shares sold in multiple open market transactions. The shares were sold at prices between $102.59 to $103.235, inclusive. The reporting person undertakes to provide to the staff of the SEC, MetLife, Inc., or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price. F3 Includes 3,073 stock options previously added to the reporting person's award through an adjustment to maintain the intrinsic value of the stock options in light of the distribution by MetLife, Inc. to its shareholders of Brighthouse Financial, Inc. common stock. The reporting person did not receive shares of Brighthouse Financial, Inc. common stock on account of the stock options. F4 The options became exercisable in three equal installments on February 28, 2018, 2019, and 2020. F5 The options became exercisable in three installments on March 2, 2019, 2020 and 2021. F6 The options became exercisable in three installments on February 26, 2020, 2021 and 2022. F7 The options become exercisable in equal installments on each of the first three anniversaries of the grant date. References:	M Exercise / conversionCommon Stock · Non-derivative	28,817A	46.85	Direct	Form 4 ↗0001535491-26-000007
2026-10-01Filed 2026-10-05	Mumenthaler Christian StephaneDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0002066326-26-000015
2026-10-01Filed 2026-10-05	Hay Laura JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0002013372-26-000016
2026-10-01Filed 2026-10-05	Seitz MichelleDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. References: F1	A Award / grantCommon Stock · Non-derivative	544A	0	Direct	Form 4 ↗0001836301-26-000020
2026-10-01Filed 2026-10-05	WEINBERGER MARK ADirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. References: F1	A Award / grantCommon Stock · Non-derivative	544A	0	Direct	Form 4 ↗0001785997-26-000010
2026-10-01Filed 2026-10-05	MCKENZIE DIANADirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0001754648-26-000015
2026-10-01Filed 2026-10-05	Johnson Jeh C.Director Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0001707516-26-000015
2026-10-01Filed 2026-10-05	Harris Carla ADirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0001707351-26-000025
2026-10-01Filed 2026-10-05	Glaser Daniel SDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. F2 These shares are held in a GRAT. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0001420864-26-000024
2026-10-01Filed 2026-10-05	HUBBARD ROBERT GLENNDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees and Board Chair retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. References: F1	A Award / grantCommon Stock · Non-derivative	941A	94.35	Direct	Form 4 ↗0001283051-26-000015
2026-10-01Filed 2026-10-05	Kennard William EDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 MetLife, Inc.'s non-management director compensation arrangements pay a portion of non-management director retainer fees in MetLife, Inc. common stock. The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. F2 Shares held in trust under the MetLife Policyholder Trust established to hold shares of common stock allocated to eligible policyholders of Metropolitan Life Insurance Company, a wholly-owned subsidiary of MetLife, Inc. References: F1	A Award / grantCommon Stock · Non-derivative	544A	94.35	Direct	Form 4 ↗0001198236-26-000015
2026-09-08Filed 2026-09-10	Mumenthaler Christian StephaneDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	21A	95.5	Direct	Form 4 ↗0002066326-26-000013
2026-09-08Filed 2026-09-10	Hay Laura JDirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	39A	95.5	Direct	Form 4 ↗0002013372-26-000014
2026-09-08Filed 2026-09-10	MCKENZIE DIANADirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	157A	95.5	Direct	Form 4 ↗0001754648-26-000013
2026-09-08Filed 2026-09-10	TADROS RAMYOfficer · President, U.S. Business Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the reporting person has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	115A	95.5	Direct	Form 4 ↗0001714199-26-000011
2026-09-08Filed 2026-09-10	Johnson Jeh C.Director Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	59A	95.5	Direct	Form 4 ↗0001707516-26-000013
2026-09-08Filed 2026-09-10	Harris Carla ADirector Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred. References: F1	A Award / grantCommon Stock · Non-derivative	42A	95.5	Direct	Form 4 ↗0001707351-26-000020

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.